Scarica l'app Stockscreener
4.5819
0.55%
0.0319
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.55
Aprire:
$4.6
Volume 24 ore:
331.01K
Relative Volume:
0.40
Capitalizzazione di mercato:
$145.94M
Reddito:
$160.43M
Utile/perdita netta:
$-227.64M
Rapporto P/E:
-0.0666
EPS:
-68.77
Flusso di cassa netto:
$-170.79M
1 W Prestazione:
-3.48%
1M Prestazione:
+0.99%
6M Prestazione:
+164.45%
1 anno Prestazione:
-24.38%
Intervallo 1D:
$4.48
$4.72
Intervallo di 1 settimana:
$4.3571
$4.73
Portata 52W:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Confronta AGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.58 | 144.98M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.05 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
597.83 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.72 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
728.02 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.16 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
RSI Check: Should I set a stop loss on Agenus Inc2025 Trade Ideas & Smart Allocation Stock Tips - خودرو بانک
Recap Report: Is Agenus Inc forming a breakout patternSell Signal & Fast Entry High Yield Stock Tips - خودرو بانک
Pullback Watch: Should you avoid Agenus Inc stock right now2025 Top Decliners & Long-Term Growth Plans - خودرو بانک
Quarterly Risk: Is Agenus Inc a good ESG investmentIPO Watch & Safe Capital Growth Plans - خودرو بانک
Moving Averages: Is TSLA a play on infrastructure spendingJuly 2025 Review & Daily Entry Point Alerts - خودرو بانک
Agenus' (AGEN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Earnings call transcript: Agenus Q2 2025 focuses on cancer therapies - Investing.com India
Earnings call transcript: Agenus Q2 2025 focuses on cancer therapies By Investing.com - Investing.com Canada
Agenus stock gains as bot/bal granted compassionate use in France - Investing.com
France Grants Reimbursed Compassionate Access for BOT/BAL in Refractory MSS Colorectal Cancer - Oncodaily
Agenus (AGEN) Analyst Rating Update: HC Wainwright & Co. Reitera - GuruFocus
Agenus’ cancer immunotherapy combo gets French compassionate access By Investing.com - Investing.com Australia
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer - BioSpace
Agenus’ cancer immunotherapy combo gets French compassionate access - Investing.com India
Agenus at H.C. Wainwright Conference: Insights on Botensilimab By Investing.com - Investing.com Canada
Agenus at H.C. Wainwright Conference: Insights on Botensilimab - Investing.com
France authorizes reimbursed compassionate use of Agenus' BOT/BAL for MSS metastatic colorectal cancer - MarketScreener
Comparing Agenus Inc. in custom built stock radarsMarket Volume Report & Capital Efficient Trading Techniques - Newser
Agenus Posts 48% Q2 Revenue Miss - AOL.com
Can Agenus Inc. keep up with sector leaders2025 Performance Recap & Daily Entry Point Trade Alerts - خودرو بانک
Risk Recap: What is Agenus Inc.’s TAM (Total Addressable Market)Weekly Market Outlook & Daily Technical Forecast Reports - خودرو بانک
Will Agenus Inc. bounce back from current supportJuly 2025 Intraday Action & Daily Volume Surge Trade Alerts - Newser
Is Agenus Inc. stock a good pick for beginners2025 Winners & Losers & Verified Momentum Stock Alerts - خودرو بانک
Aug Spikes: Is Agenus Inc.’s ROE strong enoughEarnings Risk Summary & Fast Moving Trade Plans - خودرو بانک
What MACD signals say about Agenus Inc.Earnings Overview Report & Free Technical Pattern Based Buy Signals - Newser
Agenus Inc. shares fall 2.22% intraday as the company prepares to participate in the H.C. Wainwright 27th Annual Global Investment Conference. - AInvest
What are Agenus Inc.’s earnings expectationsQuarterly Growth Report & Weekly Hot Stock Watchlists - خودرو بانک
Will Agenus Inc. benefit from macro trendsTrade Ideas & Scalable Portfolio Growth Methods - Newser
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference | AGEN Stock News - GuruFocus
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - The Globe and Mail
Agenus Inc. stock trend forecast2025 Market Outlook & Growth Focused Investment Plans - Newser
Major Colorectal Cancer Trial Update: Agenus to Present BOT/BAL Immunotherapy Progress at Global Conference - Stock Titan
Technical signs of recovery in Agenus Inc.Market Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Is Agenus Inc. still worth holding after the dipJuly 2025 Gainers & Free Real-Time Volume Trigger Notifications - Newser
Will Agenus Inc. stock recover after recent dropWall Street Watch & Verified Momentum Stock Ideas - Newser
Agenus Inc. Builds Base for Possible Rebound2025 Price Momentum & Capital Efficiency Focused Ideas - beatles.ru
Detecting support and resistance levels for Agenus Inc.2025 Price Momentum & Smart Investment Allocation Tips - Newser
Real time scanner hits for Agenus Inc. explainedBreakout Watch & Safe Capital Investment Plans - Newser
Using data tools to time your Agenus Inc. exit2025 Performance Recap & Detailed Earnings Play Strategies - Newser
Real time alert setup for Agenus Inc. performance2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - Newser
Is Agenus Inc. part of any major index2025 Biggest Moves & Risk Controlled Stock Pick Alerts - خودرو بانک
Real time pattern detection on Agenus Inc. stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Agenus Inc. forming a bullish divergenceMarket Sentiment Report & Community Consensus Picks - خودرو بانک
How moving averages guide Agenus Inc. tradingTrade Entry Summary & Target Return Focused Stock Picks - Newser
Can Agenus Inc. navigate macro headwindsWeekly Market Report & Consistent Profit Focused Trading Strategies - خودرو بانک
What is Agenus Inc. s revenue forecast2025 Investor Takeaways & Low Drawdown Momentum Trade Ideas - خودرو بانک
Can Agenus Inc. grow without external fundingJuly 2025 Gainers & Verified Chart Pattern Signals - خودرو بانک
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.07%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):